456 related articles for article (PubMed ID: 15569269)
1. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
Gromada J; Brock B; Schmitz O; Rorsman P
Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
[TBL] [Abstract][Full Text] [Related]
2. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.
Gromada J; Holst JJ; Rorsman P
Pflugers Arch; 1998 Apr; 435(5):583-94. PubMed ID: 9479010
[TBL] [Abstract][Full Text] [Related]
3. New insights into the regulation of glucagon secretion by glucagon-like peptide-1.
Gromada J; Rorsman P
Horm Metab Res; 2004; 36(11-12):822-9. PubMed ID: 15655714
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
5. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
6. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
7. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.
Holz GG
Horm Metab Res; 2004; 36(11-12):787-94. PubMed ID: 15655710
[TBL] [Abstract][Full Text] [Related]
8. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
9. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
Byrne MM; Göke B
Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
[TBL] [Abstract][Full Text] [Related]
10. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
Thorens B
Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
[No Abstract] [Full Text] [Related]
11. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
Thorens B; Waeber G
Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes.
Ahrén B
Bioessays; 1998 Aug; 20(8):642-51. PubMed ID: 9780839
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
15. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
[TBL] [Abstract][Full Text] [Related]
16. Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.
Delmeire D; Flamez D; Hinke SA; Cali JJ; Pipeleers D; Schuit F
Diabetologia; 2003 Oct; 46(10):1383-93. PubMed ID: 13680124
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 in NIDDM.
Holst JJ
Diabet Med; 1996 Sep; 13(9 Suppl 6):S156-60. PubMed ID: 8894501
[TBL] [Abstract][Full Text] [Related]
18. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37).
Holz GG; Leech CA; Heller RS; Castonguay M; Habener JF
J Biol Chem; 1999 May; 274(20):14147-56. PubMed ID: 10318832
[TBL] [Abstract][Full Text] [Related]
19. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Kjems LL; Holst JJ; Vølund A; Madsbad S
Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic and extrapancreatic effects of GLP-1.
Valverde I; Villanueva-Peñacarrillo ML; Malaisse WJ
Diabetes Metab; 2002 Dec; 28(6 Pt 2):3S85-9; discussion 3S108-12. PubMed ID: 12688638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
